In a small European cohort with de novo metastatic prostate cancer (n = 56), HLA‐A*02:01 and HLA‐A*24:02 have been suggested to have prognostic implications [4], but beyond that, little is known about the role of HLA‐type and antiviral immunity in prostate cancer. This evidence concerns the gene HLA-A and prostate carcinoma.